证券代码：688068 证券简称：热景生物 公告编号：2025-024 北京热景生物技术股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京热景生物技术股份有限公司（以下简称"公司"）2024年归属于上 市公司股东净利润为负，根据相关法律法规以及《公司章程》等规定，2024年度 拟不进行利润分配，也不进行资本公积金转增股本和其他形式的分配。 公司2024年度利润分配预案已经公司第三届董事会第二十八次会议、第 三届监事会第二十次会议审议通过，尚需提交公司2024年年度股东大会审议。 公司不触及《上海证券交易所科创板股票上市规则》（以下简称"《科 创板股票上市规则》"）第12.9.1条第一款第（八）项规定的可能被实施其他风 险警示的情形。 一、2024年度利润分配方案内容 （一）利润分配方案的具体内容 经容诚会计师事务所(特殊普通合伙)审计，公司 2024 年度归属于上市公司 股东的净利润为-191,004,566.74 元。 经公司第三届董事会第二十八次会 ...

Financial Performance - The company's revenue for 2024 was CNY 510,900,037.23, a decrease of 6.74% compared to CNY 547,836,199.48 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY -191,004,566.74, representing a significant decline of 760.40% from CNY 28,922,432.95 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY -37,162,581.27, an improvement of 23.43% compared to CNY -48,531,914.50 in 2023[22]. - The total assets at the end of 2024 were CNY 3,325,861,626.00, down 6.88% from CNY 3,571,517,927.61 at the end of 2023[23]. - The basic earnings per share for 2024 was CNY -2.12, a decrease of 742.42% from CNY 0.33 in 2023[23]. - The gross profit margin for 2024 was 55.36%, a decrease of 1.77 percentage points compared to 2023[175]. - The company reported a net loss of CNY 150.37 million in Q4 2024, with a total revenue of CNY 124.74 million for the same quarter[29]. - The company achieved operating revenue of 510.90 million yuan, a year-on-year decrease of 6.74%[171]. - The net profit attributable to the parent company was CNY -191.00 million, a year-on-year decline of 760.40%[171]. Research and Development - The company invested a total of 113.31 million yuan in R&D for 2024, accounting for 22.18% of its revenue[51]. - The R&D expenditure as a percentage of revenue for 2024 was 22.18%, a decrease of 2.08 percentage points from 24.26% in 2023[23]. - The company has developed a proprietary GlyExo-Capture® platform for liquid biopsy, achieving significant breakthroughs in glycan chain abnormal protein capture and exosome detection technologies, with international and domestic patents obtained[140]. - The company has established the "X-Gen AI Drug Discovery and Design Research Center" to accelerate drug development using advanced AI technologies[50]. - The company has undertaken a total of 12 new and ongoing research projects, including 5 national key R&D projects under the "14th Five-Year Plan"[55]. - The company has published over 20 original research papers in top-tier journals like Nature and Cell, showcasing its leading position in the in vitro diagnostics industry[152]. - The company has developed a breakthrough liver-targeted delivery technology platform, which is expected to provide broader treatment strategies for liver-targeted diseases[151]. Market and Competitive Landscape - The company operates in a highly competitive in vitro diagnostic industry, where rapid technological advancements and product updates pose risks to maintaining market competitiveness[166]. - The in vitro diagnostic industry is experiencing intensified competition, with both domestic and international players vying for market share, which could negatively impact the company's market position and profitability[168]. - The global in vitro diagnostic (IVD) market is projected to reach $118 billion in 2024, with the non-COVID IVD market growing at a rate of 6.2%[86]. - The domestic IVD industry is undergoing structural changes, with the localization rate of upstream raw materials increasing to 35%[87]. - The company is focusing on innovative drug development, leveraging AI to enhance the efficiency of antibody and nucleic acid drug pipelines[81]. Corporate Governance and Compliance - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[3]. - The company has not achieved profitability since its listing[3]. - The company has committed to improving internal governance and control systems, ensuring timely and accurate information disclosure to investors[60]. Risks and Challenges - The company faces risks related to the failure of innovative drug development, particularly during clinical trials, which could significantly impact future growth and investment expectations[161]. - The pricing of diagnostic products is subject to government policies and market competition, which may lead to price declines if the company fails to innovate and introduce new products[165]. - The company must continuously upgrade its products to meet market demands; failure to do so could adversely affect future revenue growth and profitability[162]. - Future R&D investments are expected to increase further due to the acceleration of clinical projects in associated companies, which may lead to additional investment losses for the company[160]. Product Development and Innovations - The company has developed a liver cancer risk warning model (C-GALAD) that outperforms two major international models, aiding in early liver cancer diagnosis[41]. - The company has established a digital intelligent diagnosis model for liver disease risk warning, integrating clinical data with AI algorithms[67]. - The company has launched the "GlyExo-Capture® exosome rapid separation system" and the "EXO-01 exosome microRNA automatic detection instrument," marking significant advancements in exosome extraction automation[115]. - The company has received clinical trial approvals for the SGC001 project from both the FDA and the CDE, aimed at treating acute myocardial infarction patients[113]. - The company has developed a comprehensive STAT testing solution for emergency diagnostics, achieving a new breakthrough in chemiluminescence testing with a throughput of 600 tests per hour[42]. Financial Health and Investments - The company's total foreign assets amounted to 9,059,558.81 RMB, representing 0.27% of the total assets[200]. - The company's undistributed profits decreased to 2,737,758,221.52 RMB, reflecting a decline of 7.07% compared to the previous period[200]. - The company incurred an investment loss of CNY 43.61 million from its joint ventures, which increased R&D spending in innovative drug and early cancer screening fields[25]. - The company recognized impairment losses of CNY 83.12 million during the reporting period due to intensified competition in the industry[25].

Financial Performance - The company's operating revenue for Q1 2025 was ¥93,241,595.44, a decrease of 19.71% compared to ¥116,124,860.44 in the same period last year[4] - The net profit attributable to shareholders was -¥24,008,215.62, representing a decline of 574.96% from a profit of ¥5,054,819.80 in the previous year[4] - Net profit for Q1 2025 was a loss of ¥24,566,770.04, compared to a profit of ¥3,530,809.12 in Q1 2024, representing a significant decline[16] - The company reported a total comprehensive loss of ¥24,249,332.36 for Q1 2025, compared to a comprehensive income of ¥3,530,809.12 in Q1 2024[16] - Basic and diluted earnings per share were both -¥0.26, a decline of 533.33% from ¥0.06 in the same period last year[4] - Basic and diluted earnings per share for Q1 2025 were both -¥0.26, down from ¥0.06 in Q1 2024[17] Cash Flow and Liquidity - The net cash flow from operating activities was -¥9,857,827.91, an improvement of 29.62% compared to -¥14,007,005.61 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was a net outflow of ¥9,857,827.91, an improvement from a net outflow of ¥14,007,005.61 in Q1 2024[17] - Cash and cash equivalents decreased to CNY 179,150,227.74 from CNY 270,149,505.21, representing a decline of approximately 33.73%[12] - Cash and cash equivalents at the end of Q1 2025 were ¥179,143,652.74, down from ¥234,606,511.59 at the end of Q1 2024[18] - Investment activities resulted in a net cash outflow of ¥60,210,905.55 in Q1 2025, compared to a net inflow of ¥63,265,564.93 in Q1 2024[18] - Financing activities led to a net cash outflow of ¥21,661,165.53 in Q1 2025, compared to a net outflow of ¥86,960,469.79 in Q1 2024[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,271,800,843.47, a decrease of 1.63% from ¥3,325,861,626.00 at the end of the previous year[5] - The company's current assets totaled CNY 1,469,794,285.16, an increase of 13.73% compared to CNY 1,292,423,310.23 at the end of 2024[13] - The company's total liabilities increased to CNY 289,666,459.87 from CNY 251,766,081.35, marking an increase of about 15.04%[14] - The total equity attributable to shareholders decreased to CNY 2,984,120,971.24 from CNY 3,075,526,738.85, a decline of approximately 2.97%[14] - The total non-current assets decreased to CNY 1,802,006,558.31 from CNY 2,033,438,315.77, reflecting a decline of approximately 11.37%[13] Operational Metrics - Research and development expenses totaled ¥20,426,393.23, accounting for 21.91% of operating revenue, an increase of 2.39 percentage points from 19.52%[5] - The decline in net profit was primarily due to a decrease in operating revenue and changes in product mix, leading to reduced gross profit[7] - The accounts receivable rose to CNY 113,821,794.92, up from CNY 91,877,262.84, indicating a growth of about 23.87%[12] - The company's inventory slightly decreased to CNY 80,360,959.86 from CNY 83,454,876.76, a reduction of approximately 3.36%[13] - The company reported a decrease in employee compensation payable to CNY 15,665,780.79 from CNY 20,364,491.39, a reduction of about 22.93%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,662[9]

证券代码：688068 证券简称：热景生物 公告编号：2025-026 北京热景生物技术股份有限公司 关于调整 2020 年限制性股票激励计划授予价格的 公告 （四）2020 年 6 月 8 日，公司召开 2020 年第三次临时股东大会，审议并通 过了《关于审议公司<2020 年限制性股票激励计划（草案）>及其摘要的议案》 《关于审议公司<2020 年限制性股票激励计划实施考核管理办法>的议案》以及 《关于提请公司股东大会授权董事会办理股权激励相关事宜的议案》，并于 2020 年 6 月 9 日在上海证券交易所网站（www.sse.com.cn）披露了《北京热景生物技 术股份有限公司关于公司 2020 年限制性股票激励计划内幕信息知情人及激励对 象买卖公司股票情况的自查报告》（公告编号：2020-037）。 （五）2020 年 6 月 8 日，公司召开第二届董事会第十五次会议与第二届监 事会第十二次会议，审议通过了《关于向激励对象首次授予限制性股票的议案》。 公司独立董事对该事项发表了独立意见，认为授予条件已经成就，激励对象主体 资格合法有效，确定的授予日符合相关规定。监事会对授予日的激励对象名单进 行核实并 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-028 北京热景生物技术股份有限公司 关于作废部分已授予尚未归属的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"热景生物"或"公司"）于 2025 年 4 月 28 日召开了第三届董事会第二十八次会议、第三届监事会第二十次会议 审议通过了《关于作废部分已授予尚未归属的限制性股票的议案》，现将相关事 项公告如下： 一、公司 2020 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2020 年 5 月 19 日，公司召开第二届董事会第十四次会议，会议审议通 过了《关于审议公司<2020 年限制性股票激励计划（草案）>及其摘要的议案》 《关于审议公司<2020 年限制性股票激励计划实施考核管理办法>的议案》以及 《关于提请公司股东大会授权董事会办理股权激励相关事宜的议案》等议案。公 司独立董事就本激励计划相关议案发表了明确同意的独立意见。 同日，公司召开第二届监事会第十一次会议，审议通过了《关于审 ...

证券代码：688068 证券简称：热景生物 公告编号：2025-027 北京热景生物技术股份有限公司 2020 年限制性股票激励计划首次授予部分第三个归 属期及预留授予部分第二个归属期符合归属条件的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、本次股权激励计划主要内容 （1）股权激励方式：第二类限制性股票。 （2）授予数量：本激励计划拟向激励对象授予 85.00 万股限制性股票，约 占本激励计划草案公告时公司股本总额 6,219.6341 万股的 1.37%。其中首次授予 76.00 万股，约占本激励计划草案公告时公司股本总额的 1.22%，首次授予部分 占本次授予权益总额的 89.41%；预留 9 万股，约占本激励计划草案公告时公司 股本总额的 0.14%，预留部分占本次授予权益总额的 10.59%。 公司 2020 年、2021 年年度利润分配方案已实施完毕，故限制性股票授予数 量由 85.00 万股调整为 125.80 万股。其中，首次授予数量由 76.00 万股调整为 112.48 万 ...

北京热景生物技术股份有限公司监事会 2025 年 4 月 28 日 北京热景生物技术股份有限公司监事会 关于公司 2020 年限制性股票激励计划首次授予 部分第三个归属期及预留授予部分第二个归属 期归属名单的核查意见 北京热景生物技术股份有限公司（以下简称"公司"）监事会根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上海 证券交易所科创板股票上市规则》（以下简称"《上市规则》"）等相关法律、法规、 规范性文件及《北京热景生物技术股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，对公司 2020 年限制性股票激励计划（以下简称"本次激励计划"）首次 授予部分第三个归属期及预留授予部分第二个归属期归属名单进行了核查，发表核查意 见如下： 除 4 名首次授予部分激励对象已不在公司任职不符合归属条件，3 名首次授予部分 激励对象绩效考核评估结果为"D"不满足归属条件外，公司 2020 年限制性股票激励计 划首次授予部分第三个归属期及预留授予部分第二个归属期合计 30 名激励对象（其中 ...

北京市东卫律师事务所 法律意见书 北京市东卫律师事务所 关于北京热景生物技术股份有限公司 2020年 限制性股票激励计划作废部分已授予尚未归属的限 制性股票、调整授予价格及首次授予部分第三个归属 期及预留授予部分第二个归属期符合归属条件的 法律意见书 东卫法意[2025]第0093号 北京市东卫津师事务所 BEIJING DONGWEI LAW FIRM 北京市东城区朝阳门北大街 8 号富华大厦 D3B 电话:010-65542827 传真: 010-65542185 二〇二五年四月 第 1页 共 17页 北京市东卫律师事务所 法律意见书 目 录 | 一、本次股票激励计划作废、调整及归属相关事项的批准和授权 · 5 | | --- | | 二、本次作废的主要内容 ······················· | | 三、本次授予价格调整的主要内容 | | (一)本次授予价格调整的原因 · | | (二)本次授予价格调整的方法及结果 ······· 10 | | 1、授予价格的调整 ············· 10 | | 四、本次归属的归属条件及成就情况 ················ 10 | | (一 ...

公司简称：热景生物 证券代码：688068 上海荣正企业咨询服务（集团）股份有限公司 关于 首次授予部分第三个归属期及预留授予部分第 二个归属期归属条件成就 之 北京热景生物技术股份有限公司 2020 年限制性股票激励计划 独立财务顾问报告 一、释义 | 热景生物、本公司、公司、上 | 指 | 北京热景生物技术股份有限公司 | | --- | --- | --- | | 市公司 | | | | 财务顾问、独立财务顾问 | 指 | 上海荣正企业咨询服务（集团）股份有限公司 | | 本激励计划 | 指 | 2020 北京热景生物技术股份有限公司 年限制性股票激励计 | | | 划 | | | 限制性股票、第二类限制性股 票 | 指 | 符合本激励计划授予条件的激励对象，在满足相应归属条件 后分次获得并登记的本公司股票 | | 激励对象 | 指 | 按照本激励计划规定，获得限制性股票的公司高级管理人 | | | | 员、核心技术人员、董事会认为需要激励的其他人员 | | 授予日 | 指 | 公司向激励对象授予限制性股票的日期，授予日必须为交易 | | | 日 | | | 授予价格 | 指 | 公司授予激励对象每一股 ...

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. plans to increase capital in its associate company, Beijing Shunjing Biopharmaceutical Technology Co., Ltd., through a cash investment totaling 300 million yuan, which will adjust the company's shareholding percentage in Shunjing from 45.8333% to 45.5833% [2][5][14] Summary by Sections Capital Increase and Related Transactions Overview - The capital increase will be priced at 25 yuan per registered capital, raising the registered capital of Shunjing from 60 million yuan to 72 million yuan [2][5] - The transaction constitutes a related party transaction but does not qualify as a major asset restructuring under relevant regulations [3][6] Approval Process - The proposal for the capital increase was approved in meetings held by the independent directors and the board of directors, with related directors abstaining from voting [3][15][16] - The transaction requires approval from the shareholders' meeting, with related parties waiving their voting rights [3][16] Associate Company Information - Shunjing Biopharmaceutical was established on December 21, 2018, with a registered capital of 60 million yuan, focusing on technology development and consulting [7] - The company is in its early stages, primarily engaged in the research and development of innovative drugs [7][14] Financial Data and Valuation - The capital increase is based on a fair valuation considering Shunjing's R&D capabilities and future profit potential, with a total investment of 300 million yuan [12][14] - As of December 31, 2024, Shunjing reported a net asset of -22.0544 million yuan, indicating ongoing financial challenges [4][18] Strategic Importance - The capital increase aligns with the company's strategy of enhancing its capabilities from diagnosis to treatment, supporting long-term growth and investment returns [14][15]